← Back to search
DEUTSCHES KREBSFORSCHUNGSZENTRUM
HEIDELBERG, 69120
Unclaimed
Source Records
No company-reported description yet. Owners can add one after claiming the profile.
Capabilities
Prime contracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | THIS PURCHASE ORDER INCLUDES SERVICES TO TEST NO MORE THAN 13,000 SAMPLES THAT WERE PREVIOUSLY COLLECTED IN THE ANCHOR TRIAL USING THE MULTIPLEX SEROLOGY OF UP TO 41 ANTIGENS ASSAY AT THE GERMAN CANCER RESEARCH CENTER (DKFZ). THE GOVERNMENT WILL PROV | — | $507,000 | Apr 30, 2025 | May 1, 2024 – Apr 30, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS), NATIONAL INSTITUTES OF HEALTH (NIH), NATIONAL CANCER INSTITUTE (NCI), DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS (DCEG), INFECTIONS AND IMMUNOEPIDEMIOLOGY BRANCH (IIB) REQUIRES THE TESTING OF | — | $397,800 | Jul 5, 2024 | Mar 6, 2023 – Jul 30, 2025 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | A MAJOR RESEARCH FOCUS OF THE DEPARTMENT OF APPLIED TUMOR BIOLOGY AT THE GERMAN CANCER RESEARCH CENTER (DKFZ) IS THE MOLECULAR PATHOGENESIS OF HEREDITARY COLORECTAL CANCER AND NOVEL DIAGNOSTIC AND THERAPEUTIC APPROACHES DERIVED THEREOF.
IN FRAME OF THE PROPOSED COLLABORATIVE PROJECT (APPLICATION TITLE: COMBINED CHEMO- AND IMMUNOPREVENTION FOR GASTROINTESTINAL CANCER IN A MOUSE MODEL OF LYNCH SYNDROME), THE CONTRIBUTION OF OUR DEPARTMENT WILL BE (1) THE IDENTIFICATION OF DEFINED MUTATIONS IN MOUSE LYNCH SYNDROME TUMORS, (2) THE PREDICTION AND IN VITRO EVALUATION OF TUMOR ANTIGENS GENERATED AS A CONSEQUENCE OF THESE MUTATIONS, AND (3) THE DEVELOPMENT OF AN EXPERIMENTAL VACCINE FOR TUMOR PREVENTION IN LYNCH SYNDROME MICE.
THE PLANNED CONTRIBUTION WILL BE BASED ON IN SILICO PREDICTION TOOLS TO IDENTIFY CODING MICROSATELLITES IN THE MOUSE GENOME, MUTATION TESTING OF PREDICTED CODING MICROSATELLITE TARGETS IN DNA ISOLATED FROM MOUSE TUMORS, THE VALIDATION OF THESE TARGETS IN INDEPENDENT TUMOR DNA SPECIMENS, THE GENERATION OF CODING MICROSATELLITE MUTATION-DERIVED PEPTIDES, THE IN VITRO EVALUATION OF THE IMMUNOGENICITY OF THE PEPTIDES, THE GENERATION OF PEPTIDES FOR A VACCINE, AND THE IMMUNOLOGICAL EVALUATION OF MOUSE T CELLS AND ANTIBODIES BEFORE AND AFTER VACCINATION. 16040651-02; 190332, 226569 · Prime awardUSAspending | HHSN261201500039IUSAspending | $478,148 | May 23, 2023 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced